Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Protara Therapeutics stock

TARA
US74365U1079
A2P4JE

Price

1.83
Today +/-
-0.05
Today %
-3.23 %
P

Protara Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Protara Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Protara Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Protara Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Protara Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Protara Therapeutics Stock Price History

DateProtara Therapeutics Price
9/30/20241.83 undefined
9/27/20241.89 undefined
9/26/20241.83 undefined
9/25/20241.83 undefined
9/24/20241.80 undefined
9/23/20241.89 undefined
9/20/20241.98 undefined
9/19/20241.97 undefined
9/18/20241.92 undefined
9/17/20241.82 undefined
9/16/20241.87 undefined
9/13/20241.88 undefined
9/12/20241.73 undefined
9/11/20241.70 undefined
9/10/20241.73 undefined
9/9/20241.84 undefined
9/6/20241.86 undefined
9/5/20241.90 undefined
9/4/20241.93 undefined
9/3/20241.92 undefined

Protara Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Protara Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Protara Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Protara Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Protara Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Protara Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Protara Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Protara Therapeutics’s growth potential.

Protara Therapeutics Revenue, EBIT and net profit per share

DateProtara Therapeutics RevenueProtara Therapeutics EBITProtara Therapeutics Net Income
2029e343.24 M undefined0 undefined101.43 M undefined
2028e200.59 M undefined55.69 M undefined39.07 M undefined
2027e102.69 M undefined-16.12 M undefined-16.83 M undefined
2026e3.77 M undefined-77.07 M undefined-49.94 M undefined
2025e0 undefined-64.23 M undefined-67.34 M undefined
2024e0 undefined-53.94 M undefined-64.44 M undefined
20230 undefined-43.61 M undefined-40.42 M undefined
20220 undefined-37.54 M undefined-65.95 M undefined
20210 undefined-47.49 M undefined-47.25 M undefined
20200 undefined-34.44 M undefined-33.98 M undefined
20190 undefined-15.25 M undefined-14.99 M undefined
20180 undefined-21.37 M undefined-20.73 M undefined
20170 undefined-30.36 M undefined-36.71 M undefined
20160 undefined-28.71 M undefined-28.53 M undefined
20150 undefined-20.87 M undefined-21.38 M undefined
20142.95 M undefined-7.58 M undefined-9.7 M undefined
20130 undefined-7.12 M undefined-14.03 M undefined
20120 undefined-8 M undefined-14.1 M undefined

Protara Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
002000000000003102200343
---------------3,300.0096.0871.50
------------------
000000000000000000
-8-7-7-20-28-30-21-15-34-47-37-43-53-64-77-16550
---350.00------------2,566.67-15.6927.50-
-14-14-9-21-28-36-20-14-33-47-65-40-64-67-49-1639101
---35.71133.3333.3328.57-44.44-30.00135.7142.4238.30-38.4660.004.69-26.87-67.35-343.75158.97
0.350.350.080.410.410.430.450.57.2311.2311.2611.33000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Protara Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Protara Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
7.55.283.665.341.342.121.96.2168.691.284.465.58
0000000000500242
000000000000
000000000000
0.20.211.31.41.31.40.80.91.91.32.88
7.75.484.666.642.743.423.37169.593.186.268.71
0.10.10.10.20.40.30.302.38.97.96.56
00000000039.517.90
000000000000
000000000000
0000000029.529.500
00.30.10.70.40.2001.91.61.43.69
0.10.40.20.90.80.50.3033.779.527.210.25
7.85.884.867.543.543.923.67203.2172.6113.478.95
                       
90.396.400021.521.518.50000.01
00192.3194.7198.2203209.4213.4246256.1262.7268.73
-86.7-100.5-109.9-131.3-159.8-189.7-210.5-225.5-46.8-94-160-200.38
000000000-0.2-0.7-0.03
000000000000
3.6-4.182.463.438.434.820.46.4199.2161.910268.32
0.50.40.910.60.30.40.30.911.62.43
0.711.42.64.58.92.60.323.34.23.72
04.700.500000000
03.70000000000
000000000000
1.29.82.34.15.19.230.62.94.35.86.15
000000000000
000000000000
2.9000000016.45.54.48
2.9000000016.45.54.48
4.19.82.34.15.19.230.63.910.711.310.63
7.75.784.767.543.54423.47203.1172.6113.378.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Protara Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Protara Therapeutics's financial health and stability.

Assets

Protara Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Protara Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Protara Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Protara Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-7-7-3-21-28-29-20-14-33-47-65-40
000000000000
000000000000
000014-6-1000-4
00-633330913386
000000000000
000000000000
-8-6-9-17-23-22-23-15-23-34-26-37
000000000000
72-12-1119-161822-981453
72-12-1120-161823-971553
000000000000
04000000-1000
0088002320191000
0488002320189000
------------
000000000000
0066-28-3-15-1-13168-132-1115
-8.3-6.67-10.04-17.77-23.96-22.39-23.35-15.67-24.29-35.1-26.58-37.6
000000000000

Protara Therapeutics stock margins

The Protara Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Protara Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Protara Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Protara Therapeutics's sales revenue. A higher gross margin percentage indicates that the Protara Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Protara Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Protara Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Protara Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Protara Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Protara Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Protara Therapeutics Margin History

Protara Therapeutics Gross marginProtara Therapeutics Profit marginProtara Therapeutics EBIT marginProtara Therapeutics Profit margin
2029e0 %0 %29.55 %
2028e0 %27.76 %19.48 %
2027e0 %-15.7 %-16.39 %
2026e0 %-2,042.18 %-1,323.29 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %-256.95 %-328.81 %
20130 %0 %0 %
20120 %0 %0 %

Protara Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Protara Therapeutics earnings per share therefore indicates how much revenue Protara Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Protara Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Protara Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Protara Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Protara Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Protara Therapeutics Revenue, EBIT and net profit per share

DateProtara Therapeutics Sales per ShareProtara Therapeutics EBIT per shareProtara Therapeutics Earnings per Share
2029e16.64 undefined0 undefined4.92 undefined
2028e9.72 undefined0 undefined1.89 undefined
2027e4.98 undefined0 undefined-0.82 undefined
2026e0.18 undefined0 undefined-2.42 undefined
2025e0 undefined0 undefined-3.26 undefined
2024e0 undefined0 undefined-3.12 undefined
20230 undefined-3.85 undefined-3.57 undefined
20220 undefined-3.33 undefined-5.86 undefined
20210 undefined-4.23 undefined-4.21 undefined
20200 undefined-4.76 undefined-4.7 undefined
20190 undefined-30.5 undefined-29.98 undefined
20180 undefined-47.49 undefined-46.07 undefined
20170 undefined-70.6 undefined-85.37 undefined
20160 undefined-70.02 undefined-69.59 undefined
20150 undefined-50.9 undefined-52.15 undefined
201436.88 undefined-94.75 undefined-121.25 undefined
20130 undefined-20.34 undefined-40.09 undefined
20120 undefined-22.86 undefined-40.29 undefined

Protara Therapeutics business model

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare and severe immune system disorders. It was founded in 2012 and is based in Tarrytown, New York. The company was formed through the merger of NeuroproteXeon, Inc. and Biokine Therapeutics Ltd, with the goal of developing a pipeline of novel therapeutics for rare immune system diseases. In 2018, the company was acquired by Protea Biosciences Group Inc. Protara's business model revolves around the discovery, development, and commercialization of innovative therapeutics for immune system disorders. The company utilizes various technologies and platforms, including its proprietary protein engine, to drive its innovation program. It currently has two main divisions: one focused on the development and commercialization of T-cell-engaging Bi-Specifics, a novel class of immunotherapeutics specialized in tumor antigen-specific T-cell activation, and another division offering innovative nanotechnology platforms for the development of drugs for the treatment of inflammatory and immune disorders. Protara's leading pipeline products include TULIP Bi-Specific (JNJ-63898081), a T-cell-engaging Bi-Specific against CD3 and BCMA in phase I/IIa clinical trials for patients with multiple myeloma, and RTX-240, a T-cell-engaging Bi-Specific against CD3 and PSMA in the development phase for patients with advanced solid tumors. The company also focuses on developing precursor molecules for T-cell-engaging Bi-Specifics and protein engineering and optimization technologies to enhance the effectiveness and half-life of immunotherapeutics. Additionally, Protara has proprietary nanoparticle platforms, known as NANOMAbs, with promising applications in the treatment of inflammatory and immune disorders such as COVID-19, lupus, dermal diseases, and others. In summary, Protara Therapeutics Inc is a leading biopharmaceutical company focused on innovative therapies for immune system disorders. Its pipeline includes T-cell-engaging Bi-Specifics and proprietary nanoparticle platforms with promising applications in the treatment of inflammatory and immune disorders. With its complex technology and protein development and optimization capabilities, Protara continues to create groundbreaking new treatment options for patients. Protara Therapeutics is one of the most popular companies on Eulerpool.com.

Protara Therapeutics SWOT Analysis

Strengths

Protara Therapeutics Inc has a strong focus on developing innovative drugs, leveraging advanced technologies and scientific expertise. This gives the company a competitive edge in the rapidly evolving pharmaceutical industry.

The company boasts a robust intellectual property portfolio, comprising patents, trademarks, and proprietary technologies. This provides a solid foundation for future growth, establishing barriers for potential competitors and enhancing the company's market position.

Weaknesses

At present, Protara Therapeutics Inc has a limited number of products in its portfolio. This dependence on a small product range poses a risk in terms of revenue diversification and future growth potential.

The company heavily relies on collaborations and partnerships with other entities. While such alliances may provide access to resources and expertise, they also introduce dependency on external parties, increasing the vulnerability to potential delays or conflicts in decision-making.

Opportunities

Protara Therapeutics Inc has the opportunity to expand its presence beyond its current market. Venturing into global markets could unlock new revenue streams and increase the company's market share, especially in regions with unmet medical needs.

The company has the chance to form strategic partnerships with established pharmaceutical companies or research institutions. Collaborative relationships can provide access to additional resources, expertise, and distribution networks, accelerating the development and commercialization of new drugs.

Threats

Protara Therapeutics Inc operates in a highly competitive industry, with numerous companies vying for market share. The presence of existing well-established competitors and the potential entry of new players pose threats to the company's market position and profitability.

Compliance with constantly evolving regulations and requirements within the pharmaceutical industry is a significant challenge. Protara Therapeutics Inc must navigate and adapt to regulatory changes, ensuring timely approvals and avoiding potential setbacks in drug development and commercialization.

Protara Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Protara Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Protara Therapeutics shares outstanding

The number of shares was Protara Therapeutics in 2023 — This indicates how many shares 11.331 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Protara Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Protara Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Protara Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Protara Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Protara Therapeutics stock splits

In Protara Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Protara Therapeutics.

Protara Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.82 -0.45  (44.85 %)2024 Q2
3/31/2024-0.94 -0.97  (-3.37 %)2024 Q1
12/31/2023-0.94 -0.9  (3.84 %)2023 Q4
9/30/2023-1 -0.87  (12.97 %)2023 Q3
6/30/2023-0.89 -1  (-12.04 %)2023 Q2
3/31/2023-0.89 -0.8  (10.56 %)2023 Q1
12/31/2022-0.77 -1.55  (-102.61 %)2022 Q4
9/30/2022-0.77 -0.68  (11.89 %)2022 Q3
6/30/2022-0.96 -0.8  (16.27 %)2022 Q2
3/31/2022-0.92 -0.96  (-4.19 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Protara Therapeutics stock

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

36

👫 Social

88

🏛️ Governance

46

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Protara Therapeutics shareholders

%
Name
Stocks
Change
Date
4.13022 % Shefferman (Jesse M)852,06539,6111/19/2024
2.91023 % Heights Capital Management, Inc.600,380600,3804/5/2024
2.83858 % Marshall (Randall S)585,60004/11/2023
2.07277 % The Vanguard Group, Inc.427,612012/31/2023
13.05184 % Opaleye Management Inc.2,692,594012/31/2023
1.01419 % Boxer Capital, L.L.C.209,227012/31/2023
0.96787 % Baker Bros. Advisors LP199,671012/31/2023
0.95977 % Beshar (Luke M)198,00004/11/2023
0.91451 % Ikarian Capital LLC188,664012/31/2023
0.58037 % Privium Fund Management (UK) Ltd119,730012/31/2023
1
2
3
4
5
...
7

Protara Therapeutics Executives and Management Board

Mr. Jesse Shefferman51
Protara Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 2.78 M
Dr. Jacqueline Zummo42
Protara Therapeutics Chief Scientific Operations Officer
Compensation 1.3 M
Dr. Jathin Bandari36
Protara Therapeutics Chief Medical Officer
Compensation 1.17 M
Mr. Luke Beshar64
Protara Therapeutics Independent Chairman of the Board
Compensation 197,106
Dr. Richard Levy65
Protara Therapeutics Independent Director
Compensation 123,106
1
2
3

Protara Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Chugai Pharmaceutical Stock
Chugai Pharmaceutical
SupplierCustomer-0,070,820,57-0,070,600,84
1

Most common questions regarding Protara Therapeutics

What values and corporate philosophy does Protara Therapeutics represent?

Protara Therapeutics Inc is committed to advancing innovative therapies to address unmet medical needs in the field of rare diseases and oncology. The company's corporate philosophy centers around patient-centricity, scientific excellence, and a commitment to transforming lives through the development of cutting-edge treatments. Protara Therapeutics Inc values integrity, collaboration, and a passion for making a meaningful impact in the lives of patients and their families. Through its dedication to research, development, and commercialization, Protara Therapeutics Inc strives to create value and improve outcomes for those affected by serious and life-threatening diseases.

In which countries and regions is Protara Therapeutics primarily present?

Protara Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Protara Therapeutics achieved?

Protara Therapeutics Inc has achieved several significant milestones. One of their notable achievements is the FDA approval of their lead drug candidate, TARA-002, for the treatment of lymphatic malformations. Additionally, the company has successfully completed Phase 1 clinical trials for TARA-002, demonstrating its safety and efficacy. Protara Therapeutics Inc has also expanded its pipeline by acquiring multiple preclinical stage assets, aiming to address unmet medical needs. Moreover, they have secured strategic partnerships and collaborations with renowned academic institutions and pharmaceutical companies to support their research and development efforts. These achievements highlight Protara Therapeutics Inc's commitment to advancing innovative therapies and improving patient outcomes in various disease areas.

What is the history and background of the company Protara Therapeutics?

Protara Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel therapies for rare and life-threatening diseases. Founded in 2017, Protara Therapeutics is dedicated to addressing unmet medical needs through innovative drug discovery and development. The company's research and development efforts are primarily centered around its proprietary technology platform, which allows for the design and optimization of potential novel therapies. With a commitment to improving patient outcomes, Protara Therapeutics aims to develop effective treatments for rare diseases and provide hope for patients and their families.

Who are the main competitors of Protara Therapeutics in the market?

The main competitors of Protara Therapeutics Inc in the market include major pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson. These companies have established presence and resources in the biopharmaceutical industry, which poses competitive challenges for Protara Therapeutics Inc. Additionally, there are various smaller biotech companies focusing on similar therapeutic areas, including rare diseases and oncology, making the competitive landscape dynamic and diverse.

In which industries is Protara Therapeutics primarily active?

Protara Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Protara Therapeutics?

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative treatments for rare and life-threatening diseases. The company's business model revolves around the research, development, and commercialization of novel therapies to address unmet medical needs. Protara Therapeutics Inc specializes in targeted protein degradation and immunology-based therapies, aiming to deliver transformative medicines for patients worldwide. With a strong commitment to strategic collaborations and comprehensive clinical trial programs, Protara Therapeutics Inc aims to bring groundbreaking therapies to market, improving patient outcomes and advancing healthcare in the process.

What is the P/E ratio of Protara Therapeutics 2024?

The Protara Therapeutics P/E ratio is -0.32.

What is the P/S ratio of Protara Therapeutics 2024?

The Protara Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Protara Therapeutics?

The AlleAktien quality score for Protara Therapeutics is 4/10.

What is the revenue of Protara Therapeutics 2024?

The revenue cannot currently be calculated for Protara Therapeutics.

How high is the profit of Protara Therapeutics 2024?

The expected Protara Therapeutics profit is -64.44 M USD.

What is the business model of Protara Therapeutics

Protara Therapeutics Inc is a US-based biotech company headquartered in New York. It focuses on the development of novel therapeutics that can be used to treat various oncological, neuropathological, and immunological diseases. Protara utilizes innovative technologies to selectively release the active substances at the desired body locations. One of Protara's main divisions is oncology research. The company develops innovative therapeutics that help fight tumor cells while protecting healthy cells. Protara employs peptides that can selectively bind to tumor cells and release the active substances. This technology has the potential to significantly increase the effectiveness of cancer drugs while reducing their side effects. Another division of Protara is neuropathology research. Therapeutics are developed to treat various neurological diseases, including multiple sclerosis, Parkinson's, and Alzheimer's. Protara also utilizes innovative technologies to target the affected regions of the brain and release the active substances. The company collaborates closely with experts in neurology to develop the best possible therapeutics. The third division of Protara is immunology research. Therapeutics are developed to regulate and strengthen the immune system. The company uses peptides and other substances that can interact specifically with certain immune cells. This approach aims to effectively treat autoimmune diseases such as lupus or rheumatism. One important product of Protara is the medication MEDI9197, used to treat various solid tumors. The medication stimulates the immune system to recognize and fight tumor cells, effectively destroying them and reducing the risk of tumor-related inflammations. Protara's business model is based on the development of innovative therapeutics that improve patients' health using peptide-based substances. The company collaborates closely with researchers and experts from various fields to develop the best possible therapeutics. Protara also works closely with the academic world to benefit from the latest developments and knowledge. Moreover, it collaborates with the industry to translate its therapeutics into practical applications. Protara cooperates with various partners from the pharmaceutical and biotech industry to develop, produce, and market its therapeutics. In summary, Protara Therapeutics has a promising business model based on the development of innovative therapeutics. With its unique technology and a focus on collaboration with researchers and the industry, the company is well-positioned to continue growing and developing therapeutics that truly help patients.

What is the Protara Therapeutics dividend?

Protara Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Protara Therapeutics pay dividends?

The dividend cannot currently be calculated for Protara Therapeutics or the company does not pay out a dividend.

What is the Protara Therapeutics ISIN?

The ISIN of Protara Therapeutics is US74365U1079.

What is the Protara Therapeutics WKN?

The WKN of Protara Therapeutics is A2P4JE.

What is the Protara Therapeutics ticker?

The ticker of Protara Therapeutics is TARA.

How much dividend does Protara Therapeutics pay?

Over the past 12 months, Protara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protara Therapeutics?

The current dividend yield of Protara Therapeutics is .

When does Protara Therapeutics pay dividends?

Protara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protara Therapeutics?

Protara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protara Therapeutics located?

Protara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protara Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Protara Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Protara Therapeutics in the year 2023?

In the year 2023, Protara Therapeutics distributed 0 USD as dividends.

In which currency does Protara Therapeutics pay out the dividend?

The dividends of Protara Therapeutics are distributed in USD.

All fundamentals about Protara Therapeutics

Our stock analysis for Protara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.